Difference between revisions of "Sacituzumab govitecan (Trodelvy)"

Revision as of 23:54, 24 April 2020

Mechanism of action

From the NCI Drug Dictionary: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis.

Preliminary data

TNBC

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 1;35(19):2141-2148. Epub 2017 Mar 14. link to original article PubMed

Non-small cell lung cancer

Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. Epub 2017 May 26. link to original article PubMed

History of changes in FDA indication

4/22/2020: Granted accelerated approval for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.

Also known as

Code names: IMMU-132, RS7-SN38
Generic name: sacituzumab govitecan-hziy
Brand name: Trodelvy

@@ Line 8: / Line 8: @@
 ===[[Non-small cell lung cancer]]===
 * Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. Epub 2017 May 26. [https://doi.org/10.1200/JCO.2016.72.1894 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28548889 PubMed]
+==History of changes in FDA indication==
+*4/22/2020: Granted accelerated approval for adult patients with metastatic triple-negative [[breast cancer]] who received at least two prior therapies for metastatic disease.
 ==Also known as==
-*'''Code name:''' RS7-SN38
+*'''Code names:''' IMMU-132, RS7-SN38
+*'''Generic name:''' sacituzumab govitecan-hziy
+*'''Brand name:''' Trodelvy
 [[Category:Drugs]]
 [[Category:Intravenous medications]]
 [[Category:Antibody-drug conjugates]]
@@ Line 20: / Line 24: @@
 [[Category:Topoisomerase inhibitors]]
-[[Category:Investigational drugs]]
+[[Category:Breast cancer medications]]
+[[Category:Non-small cell lung cancer medications]]
+[[Category:FDA approved in 2020]]